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Abstract
Background: Bronchiectasis is characterized by abnormal, permanent and irreversible dilatation of the bronchi,
usually responsible for daily symptoms and frequent respiratory complications. Many causes have been identified,
but only limited data are available concerning the association between bronchiectasis and renal transplantation.
Methods: We conducted a retrospective multicenter study of cases of bronchiectasis diagnosed after renal
transplantation in 14 renal transplantation departments (French SPIESSER group). Demographic, clinical, laboratory
and CT scan data were collected.
Results: Forty-six patients were included (mean age 58.2 years, 52.2 % men). Autosomal dominant polycystic kidney
disease (32.6 %) was the main underlying renal disease. Chronic cough and sputum (50.0 %) were the major
symptoms leading to chest CT scan. Mean duration of symptoms before diagnosis was 1.5 years [0–12.1 years].
Microorganisms were identified in 22 patients, predominantly Haemophilus influenzae. Hypogammaglobulinemia
was observed in 46.9 % patients. Bronchiectasis was usually extensive (84.8 %). The total bronchiectasis score was
7.4 ± 5.5 with a significant gradient from apex to bases. Many patients remained symptomatic (43.5 %) and/or
presented recurrent respiratory tract infections (37.0 %) during follow-up. Six deaths (13 %) occurred during
follow-up, but none were attributable to bronchiectasis.
Conclusions: These results highlight that the diagnosis of bronchiectasis should be considered in patients
with de novo respiratory symptoms after renal transplantation. Further studies are needed to more clearly
understand the mechanisms underlying bronchiectasis in this setting.
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Background
Renal transplantation is the most common form of solid
organ transplantation. Acute and chronic rejections are
the most dreaded complications. The main immunosup-
pressive drugs used to control allograft rejection include
corticosteroids, calcineurin inhibitors (cyclosporine A,
tacrolimus) and inhibitors of T- and B-cell proliferation
(mycophenolic acid (MPA) including mycophenolate
mofetil (MMF) and mycophenolate sodium). The most
common adverse effect of these immunosuppressive
drugs is increased susceptibility to infections, mainly
lung infections [1].
Bronchiectasis is an acquired anatomical disorder
characterized by permanent and irreversible abnormal
dilatation of the bronchi [2]. Chronic productive cough,
recurrent exacerbations, pneumonia and hemoptysis are
the main symptoms. High-resolution computed tomog-
raphy (HRCT) is required to establish the diagnosis [3].
Many causes of bronchiectasis have been identified, such
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as postinfectious, congenital or underlying anatomical or
systemic disease [4, 5]. Of note, neither renal transplant-
ation nor immunosuppressive drugs are usually consid-
ered to be potential causes of bronchiectasis. Several
studies have recently reported the development of bron-
chiectasis in adults [6, 7] and children [8–10] after renal
transplantation and hypothesized that MPA, used since
1996, might be a causative agent.
The objectives of this study were to analyze the char-
acteristics of a series of cases of bronchiectasis observed




This retrospective multicenter study was conducted in
14 renal transplantation departments participating in the
French SPIESSER group. Each center was asked to iden-
tify patients with bronchiectasis occurring after renal
transplantation. Nine centers (Reims, Angers, Limoges,
Hôpital Européen Georges Pompidou in Paris, Hôpital
Necker in Paris, Rennes, Rouen, Strasbourg, Tours)
identified eligible patients with bronchiectasis diagnosed
after renal transplantation from 1982 to 2014.
Inclusion criteria were a diagnosis of bronchiectasis
after renal transplantation, and age 18 years or older.
Exclusion criteria were bronchiectasis diagnosed before
renal transplantation, no available CT scan for confirm-
ation of the diagnosis or very incomplete clinical data
(Fig. 1). The ethical approval was obtained multi-centre.
The authorization to access patient data was obtained
from the French Advisory Committee for Data Process-
ing in Health Research (CCTIRS, Comité Consultatif sur
le Traitement de l’Information en matière de Recherche
dans le domaine de la Santé) (n°13.018) and approved by
the national commission for the personal data protection
(CNIL, Comité National de l’Informatique et des Liber-
tés) (n° 913412). The collection and analyses of the data
were fully anonymised.
A standard form was used to collect demographic, clin-
ical and laboratory data from each patient’s medical re-
cords. Obstructive disorder was defined by FEV1/FVC< 0.7
before bronchodilatators.
CT scan
Each CT scan was reviewed by a panel of pulmonolo-
gists (SD, FL, GD) and chest radiologist (OT) with a
final consensus interpretation. All CT scans reviewed
were performed with the patient in the supine position
at end-inspiratory volume using multidetector CT
scanners. One- to 5- mm-thick slices at 5- to 10-mm
intervals were analyzed from the lung apices to the
lung bases. The diagnosis of bronchiectasis was de-
fined by an airway lumen inner diameter greater than
the diameter of the accompanying pulmonary artery,
absence of tapering of bronchi, and visualization of
bronchi within 1 cm of the pleural surface [3]. As pro-
posed by Diederich et al., the extent of bronchiectasis
was classified into five categories on a lobar basis [11],
and a progressive score was used to quantify bronchi-
ectasis in each lobe: no involvement (0), less than
25 % involvement (1), 26–50 % involvement (2), 51–
75 % involvement (3) and greater than 75 % involve-
ment (4) resulting in a maximum score of 24 per
patient. The lingula was considered to be a separate
lobe for this analysis. The distribution of bronchiec-
tasis was defined as follows: localized (one lobe af-
fected) or extensive (at least two lobes affected). The
type of bronchiectasis was assessed as cylindrical, vari-
cose or cystic [3]. Other CT findings related to bron-
chiectasis were recorded: pulmonary consolidations,
bronchiolar nodules, mucoid impactions and pulmon-
ary atelectasis. When multiple CT scans were per-
formed following the diagnosis of bronchiectasis, all
scans were assessed but only the most recent scan was
selected for long-term follow-up analysis. The longitu-
dinal changes in CT-scan were defined as follows:
worsening (subsequent score of bronchiectasis greater
than initial score), stabilization (subsequent score
identical to initial score) and improvement (subse-
quent score less than initial score).
Statistical analysis
Statistical analysis was performed using EpiInfo statis-
tical software (version 3.2.2). Data are expressed as
mean ± standard deviation [minimum, maximum].
Comparisons were performed with Fisher’s exact test
Fig. 1 Flowchart of patient selection for the study
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and Student t test. A p value < 0.05 was considered
significant.
Results and discussion
Forty-six of the 77 eligible patients were included in the
study (Fig. 1) from Reims (n = 18), Rouen (n = 9), Hôpital
Necker in Paris (n = 8), Tours (n = 4), Strasbourg (n = 3),
Angers (n = 1), Rennes (n = 1), Hôpital Européen
Georges Pompidou in Paris (n = 1) and Limoges (n = 1).
Patient characteristics
Clinical characteristics at the time of diagnosis of bron-
chiectasis are summarized in Table 1. The mean age was
58.2 years. Twenty-four patients (52.2 %) were men.
Chronic cough and sputum (50 %) were the main
symptoms leading to chest CT scan. The mean dur-
ation of symptoms before diagnosis was 1.5 years.
Most patients had undergone only one renal transplant-
ation (89.1 %). Autosomal dominant polycystic kidney dis-
ease (ADPKD) (32.6 %) was the main underlying renal
disease. Immunosuppressive drugs used prior to the diag-
nosis of bronchiectasis are listed in Table 1. All patients
received steroids and all but three of the patients received
MPA (93.5 %).
Few patients exhibited respiratory symptoms before
renal transplantation, including chronic cough (n = 3),
dyspnea (n = 2), annual bronchitis (n = 2) and pneumo-
nia (n = 1). No patient exhibited chronic sputum. Eight-
een patients (40.9 %) were current or former smokers
and two had a diagnosis of chronic obstructive pulmon-
ary disease. Significant pre-existing extrarenal medical
conditions were unusual, including mycobacterial infec-
tion (n = 1) and rheumatoid arthritis (n = 1) (Table 2).
No case of chronic respiratory bacterial colonization was
identified.
CT scans
Bronchiectases were cylindrical (100 %) and usually ex-
tensive (84.8 %). Table 3 describes the characteristics of
the chest CT scan. The mean total bronchiectasis score
was 7.4 ± 5.5 with a significant gradient from apex to
bases. Bronchiolar nodules (41.3 %) and mucoid impac-
tions (21.7 %) were the most common associated CT
scan findings.
Chest X-ray prior to renal transplantation was avail-
able for 36 patients and was considered to be normal.
Chest CT scan was performed before (n = 3) or just after
(n = 9) renal transplantation in 12 patients and demon-
strated no signs of bronchiectasis.
Spirometry, laboratory, and microbiological data
Spirometry, laboratory and microbiological examinations
were performed inconstantly at the time of diagnosis of
bronchiectasis (Table 4). For patients with available data
Table 1 Demographic and Clinical Characteristics at the Time of
Diagnosis
Variables Total (n = 46)
Male 24 (52.2)
Age (years) 58.2 ± 13.6 [20.4–82.1]
Duration of symptoms before diagnosis (years) 1.5 ± 2.3 [0–12.1]
Presenting symptoms
Cough and sputum > 3 months 23 (50.0)
Hemoptysis 2 (4.3)
Single respiratory tract infection 14 (30.4)
Recurrent bronchitis 16 (34.8)
Recurrent pneumonia 9 (19.6)
Incidental 3 (6.5)
Interval between first renal transplantation and
first symptoms (years)
9.1 ± 7.3 (0.2–25.3)
Interval between first renal transplantation and
diagnosis (years)
10.9 ± 7.5 (0.4–32.0)
Cause of end-stage renal disease
Chronic glomerulonephritis 10 (21.7)
Diabetic nephropathy 0 (0)
Autosomal dominant polycystic kidney disease 15 (32.6)
Chronic tubulointerstitial nephritis 11 (23.9)
Unknown cause of end-stage renal disease 4 (8.7)
Other renal disease 6 (13.0)
Age at the first renal transplantation (years) 47.3 ± 15.1 [9.4–72.9]
Number of renal transplantations
One renal transplantation 41 (89.1)
Two renal transplantations 4 (8.7)
Three renal transplantations 1 (2.2)
Immunosuppressive regimen
Induction therapy













Data are expressed as frequency (percentage) or mean ± standard deviation
[minimum, maximum]
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(n = 36), mean lymphocyte count was 1295 cells/mm3.
Hypogammaglobulinemia, defined as gammaglobulins
less than 9 g/dL and/or IgG less than 7 g/L, was ob-
served in 15 patients (46.9 %) associated with lymphope-
nia in all but one case. Mean MPA area under the
concentration-time curve (AUC) evaluated in 21 patients
was 42.1 mg.h/L for a mean MPA daily dose of 1.5 g/day.
Spirometry was available for 22 patients and showed an
obstructive disorder in 8 cases (36.4 %). Microbiological
data were obtained in 34 cases from sputum analyses
(n = 4) or fiberoptic bronchoscopy procedure (n = 30).
Microorganisms were identified in 22 cases. Haemophilus
influenzae was the most common pathogen. Concomitant
pathogens were associated with Haemophilus influenzae
Table 2 Pulmonary Status and Comorbidities before Renal
Transplantation
Variables Total (n = 46)
Respiratory symptom
Chronic cough 3 (6.5)
Chronic sputum 0 (0)
Dyspnea 2 (4.3)
Respiratory tract infection 3 (6.5)
Annual bronchitis 2 (4.3)
Pneumonia 1 (2.2)
Smoker (current or former)a 18 (40.9)
Pack-years 19.4 ± 10.2 (5–40)
Chronic obstructive pulmonary disease 2 (4.3)
Asthma 1 (2.2)
Mycobacterial infection 1 (2.2)
Comorbid illnesses
Gastroesophageal reflux disease 17 (37.0)
Sinusitis 8 (17.4)
Rheumatoid arthritis 1 (2.2)
Data are expressed as frequency (percentage) or mean ± standard deviation
[minimum, maximum]
aMissing data for 2 patients
Table 3 CT scan features at the Time of Diagnosis




Total bronchiectasis score 7.4 ± 5.5 [1–24]
Right upper lobe 1 ± 1 [0–4]
Middle lobe 1.2 ± 1.4 [0–4]
Right lower lobe 1.6 ± 1.4 [0–4]
Culmen 0.7 ± 1.0 [0–4]
Lingula 1.0 ± 1.0 [0–4]
Left lower lobe 1.9 ± 1.5 [0–4]
Associated signs
Mucoid impactions 10 (21.7)
Pulmonary atelectasis 4 (8.7)
Bronchiolar nodules 19 (41.3)
Pulmonary consolidations 2 (4.3)
Data are expressed as frequency (percentage) or mean ± standard deviation
[minimum, maximum]
Table 4 Laboratory, Microbiology, Spirometry Data at the time
of the Diagnosis of Bronchiectasis
Variables Total (n = 46)
Serum creatinine (μmol/L) 155.9 ± 83.5 [63.0–602.0]
Creatinine clearance (mL/min,
MDRD formula)
46.4 ± 25.6 [17.0–173.0]
Lymphocytes (/mm3) (n = 36) 1295 ± 717 [19–3200]
B Lymphocytes (n = 19) 182 ± 296 [1–1194]
T Lymphocytes (n = 19) 781 ± 646 [17–2029]
CD4+ T Lymphocytes (n = 19) 562 ± 446 [9–1786]
CD8+ T Lymphocytes (n = 19) 352 ± 296 [8–1287]
Electrophoresis (n = 21)
Gammaglobulins (g/L) 8.0 ± 2.7 [4.0–14.0]
Immunoglobulin assays (n = 18)
IgG (g/L) 8.2 ± 3.2 [3.2–15.5]
IgG1 (g/L) (n = 8) 5.6 ± 3.4 [0–11.1]
IgG2 (g/L) (n = 8) 2.0 ± 1.3 [0–4.1]
IgG3 (g/L) (n = 8) 0.3 ± 0.1 [0–0.5]
IgG4 (g/L) (n = 8) 0.2 ± 0.3 [0–0.8]
IgA (g/L) 1.4 ± 0.8 [0.2–3.5]
IgM (g/L) 0.6 ± 0.4 [0.1–1.4]
Hypogammaglobulinemiaa 15 (46.9)
MPA treatment at time of diagnosis 42 (91.3)
MPA daily dose (g) (n = 41) 1.5 ± 0.6 [0.5–3.5]
MPA area under the curve (n = 21, mg.h/L) 42.1 ± 15.4 [20.5–80.0]
Spirometry (n = 22)
Obstructive disorder 8 (36.4)
Microbiological data (n = 34)
Sputum 4
Fiberoptic Bronchoscopy 30




Methicillin-resistant Staphylococcus aureus 1
Aspergillus fumigatus 2
Other bacteria 4
Data are expressed as frequency (percentage) or mean ± standard deviation
[minimum, maximum]
aDefined as gammaglobulins less than 9 g/dL and/or IgG less than 7 g/L, and
available for 32 patients either by electrophoresis and/or
immunoglobulin assay
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in 7 patients, including Streptococcus species (n = 2),
Aspergillus fumigatus (n = 2), Escherichia coli (n = 2), and
Pseudomonas aeruginosa (n = 1) (data not shown).
Initial management and outcome
MPA was stopped at the time of diagnosis of bronchiec-
tasis in 3 patients and during follow-up in another 8 pa-
tients. Immunoglobulin replacement therapy was initiated
in 6 patients either at the time of diagnosis (n = 3) or dur-
ing follow-up (n = 3). The main symptoms reported after
the diagnosis of bronchiectasis were chronic sputum
(43.5 %) and recurrent respiratory tract infections
(37.0 %). None of the six deaths (13 %) was attributable to
bronchiectasis (Table 5).
Longitudinal changes in CT scan
At least one chest CT scan was performed after the diag-
nosis of bronchiectasis in 28 patients (60.9 %). The last
CT scan available for each patient was performed 2.6 ±
2.5 years after the diagnosis of bronchiectasis. A trend
towards worsening of the total bronchiectasis score was
observed at follow-up for these 28 patients (7.7 ± 6.2 vs.
10.9 ± 6.7; p = 0.07). Bronchiectasis was more extensive
in 19 patients (67.9 %), while stabilization was observed
in 3 patients (10.7 %) and improvement was observed in
6 patients (21.4 %). Bronchiolar nodules were more fre-
quent (p = 0.01).
Discussion
To our knowledge, this study reports the largest series
of bronchiectasis diagnosed after renal transplantation.
The main finding of this study is that the clinical and
microbiological characteristics of bronchiectasis are
similar to those usually described in non-cystic fibrosis
(CF) bronchiectasis [12]: (1) chronic sputum or recur-
rent bronchitis are the most common symptoms; (2) an
obstructive disorder is frequently associated; (3) Hae-
mophilus influenzae is the most common micro-
organism identified. However, some results need to be
highlighted. First, bronchiectasis can be diagnosed very
late after renal transplantation, as illustrated by the two
previous reports in adults with a mean time to diagnosis
ranging from 3 to 11.7 years [6, 7]. Second, a CT scan
gradient was observed from the apex to the bases. Previ-
ous reports have described a predominance of bronchi-
ectasis in lower lobes in 3 patients, while the
distribution of bronchiectasis was not specified in the
other 12 cases [6–8]. Interestingly, other forms of non-
CF bronchiectasis also exhibit such predominance in the
bases [13, 14]. Third, the bronchiectasis score frequently
deteriorated during follow-up. As observed in our study,
some previous reports have shown that patients with
non-CF bronchiectasis had persistent or worsening
symptoms on long-term follow-up [15], but very limited
data are available on the course of bronchiectasis based
on follow-up CT scan score [16, 17]. Finally, the overall
mortality in our series was 13 % with a median follow-
up of 3 years, similar to the results of recent studies that
have reported mortality rates ranging between 16.3 % at
4 years and 29.7 % at 13 years in non-CF bronchiectasis
[18–20]. In a long-term prospective study, Loebinger et
al. found that the primary cause of death was respiratory
(70.4 %), especially respiratory infection or failure [19].
In contrast, despite frequent respiratory infections, no
death was related to a respiratory cause in our series.
Prior to the study by Pijnenburg et al. in 2004, no
case of bronchiectasis occurring after renal trans-
plantation had been reported in the literature [8]. In
our study, only two patients had a diagnosis of bron-
chiectasis before 2004 (data not shown). Bronchiecta-
ses were then mainly diagnosed within the ten last
years, which may be related to expanded indications
of CT-scan and changes in immunosuppression strat-
egy. The absence of systematic chest CT scan before
or just after renal transplantation does not allow pre-
existing bronchiectasis to be formally excluded. A
chest CT scan without bronchiectasis was available
for only 12 patients (three before and nine after renal
transplantation). The presence of asymptomatic bron-
chiectasis before transplantation in some cases there-
fore cannot be formally excluded. In particular, one
patient had rheumatoid arthritis and another had a
history of mycobacterial infection, two potential
causes of bronchiectasis [12, 21]. Moreover, patients
with ADPKD could also be at increased risk of
Table 5 Follow-up Data
Variables Total (n = 46)
Medical decision at the time of diagnosis
MPA withdrawal 3
Immunoglobulin replacement therapy 3
Follow-up after diagnosis (months) 36.3 ± 33.3 [1–150]
Cough and chronic sputum 20 (43.5)
Respiratory tract infections 17 (37.0)
Number of episodes of acute bronchitis per year 0.2 ± 0.5 [0–2]
Number of episodes of pneumonitis per year 0.07 ± 0.2 [0–0.6]
Subsequent medical decision (n = 45)
Unchanged 35
MPA withdrawal 8
Immunoglobulin replacement therapy 3
Death 6 (13 %)
Interval between diagnosis of bronchiectasis
and death (years)
5.3 ± 4.4 [1.2–11.0]
Respiratory causes 0 (0)
Data are expressed as frequency (percentage) or mean ± standard deviation
[minimum, maximum]
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bronchiectasis, as recent studies have demonstrated
an increased prevalence of mild-to-moderate cylin-
drical bronchiectasis with bilateral lower lung pre-
dominance in ADPKD [22–24]. ADPKD is associated
with defective primary ciliary function in renal epithe-
lial cells. Functional abnormalities in polycystin-1 and
2, two membrane regulatory proteins expressed in the
cilia of both human airway epithelial and airway
smooth muscle cells, may result in radiological bron-
chiectasis due to decreased mucociliary clearance or
impaired airway injury repair [22, 24]. However, these
studies present a number of limitations including the
absence of data on comorbidities associated with
bronchiectasis [22] and the inclusion of transplant re-
cipients [23]. At least, the minimal interval 0.4 year
between first renal transplantation and diagnosis of
bronchiectasis, probably too short to develop bronchiec-
tasis, argues for undetected pre-existing bronchiectasis.
Bronchiectasis can be induced by primary or second-
ary immunodeficiency [12, 21, 25, 26]. Drug-induced im-
munosuppression following transplantation predisposes
to recurrent lung infections and increases the risk of
bronchiectasis after bone marrow, heart or lung trans-
plantation [27–29]. Low immunoglobulin and mannose
binding protein levels after renal transplantation are as-
sociated with infectious complications [30]. In our series,
15 patients exhibited hypogammaglobulinemia, which
may contribute to the development of bronchiectasis [7].
Three recent studies have suggested that MPA may
be a causative factor of bronchiectasis [6–8]. MPA is
a relatively new immunosuppressive drug commonly
used in renal transplantation for the prevention and
treatment of allograft rejection. According to the re-
sults of these three studies, the potential involvement
of MPA is based on the following arguments: 1) some
patients did not have any respiratory symptoms des-
pite long periods with other immunosuppressive drugs
[8]; 2) an improvement of symptoms after MPA with-
drawal was observed in some patients [6]; 3) some
cases of bronchiectasis have been described in chil-
dren who have received renal transplantation with
MPA, whereas bronchiectasis is usually very uncom-
mon at this age in the absence of CF or immunodefi-
ciency [8]. In our series, five patients not treated by
MPA for a first renal transplantation developed symp-
tomatic bronchiectasis after a second or third renal
transplantation with MPA treatment. Two mecha-
nisms have been proposed to explain the role of MPA
in bronchiectasis. First, MPA, as a potent inosine
monophosphate dehydrogenase inhibitor, inhibits pur-
ine synthesis and severely depresses both cell-
mediated and humoral immunity by inhibiting T- and
B-cell proliferation. The resulting hypogammaglobuli-
nemia has been shown to be more frequent and more
severe in patients receiving MPA compared to other
immunosuppressive drugs [31]. Only six of the 15 pa-
tients with hypogammaglobulinemia in our study re-
ceived immunoglobulin replacement therapy. Second,
MPA may directly affect bronchial epithelium by
altering mucociliary clearance [32].
Our results should be interpreted in the context of the
several limitations of this study. 1) The retrospective
identification of the cases of bronchiectasis revealed
after renal transplantation is a major limitation. Even if
the study design was as rigorous possible, we can not ex-
clude that a significant number of cases have not been
identified by the centres. 2) The retrospective design of
this study does not allow estimating the prevalence of
the disease. 3) Thoracic CT scans were analysed in all
the cases by a panel of pulmonologists, and radiologist.
Cases were included in the study in presence of defined
bronchiectasis. However, since HRCT scan was not avail-
able for each patients, we cannot rule out that distal
bronchiectasis should not be visualized in some patients.
4) Observation bias may exist, even if it has been mini-
mized by using a standardized data collection form. In
particular, information on respiratory medical history
may have been underreported. 5) The spirometry, bio-
logical and microbiological data were very heteroge-
neous. Moreover, the role of potentially pathogenic
micro-organisms in the clinical course of bronchiectasis
cannot be determined in absence of repeated respiratory
samplings, micro-organisms quantification and charac-
terisation of associated clinical status. 6) No conclusion
can be drawn on the interest of MPA withdrawal or im-
munoglobulin replacement therapy due to the retro-
spective design and the small number of patients.
Despite these limitations, we believe that our study pro-
vides important findings on the characteristics of bron-
chiectasis occurring after renal transplantation.
Finally, it should be stressed that, even after intensive
investigation, one or more causative factors are identi-
fied in only 47 % of cases of bronchiectasis [21]. It can
therefore be hypothesized that multifactorial mecha-
nisms, including underlying diseases, immunosuppres-
sive drugs and respiratory tract infections, could
contribute to the pathogenesis or clinical emergence of
bronchiectasis after renal transplantation. Due to the
retrospective design of our study and the small number
of patients, we were not able to perform subgroup ana-
lyses in order to determine the burden of causal vari-
ables such as ADPKD, MPA and immunoglobulin
deficiency. Similar studies would be interesting in other
solid organ (liver and heart) transplantation.
Conclusion
These results highlight the fact that the diagnosis of
bronchiectasis and the practice of a chest CT-scan
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should be considered in renal transplant recipients exhi-
biting respiratory symptoms such as cough and recur-
rent respiratory tract infections. The pathophysiological
mechanisms remain to be elucidated and require further
studies. In particular, the role of MPA, the long-term
course, and the therapeutic management of bronchiec-
tasis in this setting have yet to be defined.
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